Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma

Hiroko Nishida, MDPhD, Mutsumi Hayashi, MD, PhD, Chikao Morimoto, MD, PhD, Michiie Sakamoto, MD, PhD, Taketo Yamada, MD,PhD

Blood (2017) 130 (Supplement 1): 4424.

https://doi.org/10.1182/blood.V130.Suppl_1.4424.4424

Published: 2017

Journal Articles

CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma

Hiroko Nishida, MD, PhD, Hiroko Madokoro, Hiroshi Suzuki, Mutsumi Hayashi, MD, PhD, Chikao Morimoto, MD, PhD, Michiie Sakamoto, MD, PhD, Taketo Yamada, MD, PhD

Blood (2015) 126 (23): 1809.

https://doi.org/10.1182/blood.V126.23.1809.1809

Published: 2015

Journal Articles

CD26 Expression on T-Cell Lines Is Associated with SDF-1α-Mediated Invasion and Phosphorylation of Signaling Molecules.

Pamela A. Havre, PhD, Masako Abe, PhD, Yasuyo Urasaki, PhD, Chikao Morimoto, MD, PhD, Nam H. Dang, MD, PhD

Blood (2007) 110 (11): 3572.

https://doi.org/10.1182/blood.V110.11.3572.3572

Published: 2007

Journal Articles

Characterization of Cancer Stem Cells in Human B-Cell Lymphoid Hematologic Malignancies.

Hiroko Nishida, MD, Hiroto Yamazaki, MD, PhD, Yasuo Ikeda, MD, PhD, Chikao Morimoto, MD, PhD

Blood (2007) 110 (11): 3384.

https://doi.org/10.1182/blood.V110.11.3384.3384

Published: 2007

Journal Articles

A Novel Mechanism for Imatinib Mesylate (STI571) Resistance in CML Cells: Contribution of TC-PTP to Modulating Signals Down-Stream from the BCR-ABL Fusion Protein.

Takatsune Shimizu, MD, Yoshitaka Miyakawa, MD, Satoshi Iwata, MD, Akiko Kuribara, BS, Tony Tiganis, PhD, Chikao Morimoto, MD, Yasuo Ikeda, MD, Masahiro Kizaki, MD

Blood (2004) 104 (11): 1984.

https://doi.org/10.1182/blood.V104.11.1984.1984

Published: 2004

Journal Articles

CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin.

Toshiko Yamochi, MD, PhD, Tadanori Yamochi, PhD, Ugur Aytac, PhD, Tsutomu Sato, MD, PhD, Chikao Morimoto, MD, Nam H. Dang, MD, PhD

Blood (2004) 104 (11): 3407.

https://doi.org/10.1182/blood.V104.11.3407.3407

Published: 2004

NARROW

Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma

CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma

CD26 Expression on T-Cell Lines Is Associated with SDF-1α-Mediated Invasion and Phosphorylation of Signaling Molecules.

Characterization of Cancer Stem Cells in Human B-Cell Lymphoid Hematologic Malignancies.

A Novel Mechanism for Imatinib Mesylate (STI571) Resistance in CML Cells: Contribution of TC-PTP to Modulating Signals Down-Stream from the BCR-ABL Fusion Protein.

CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin.

Email alerts

ASH Publications

American Society of Hematology

Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma

CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma

CD26 Expression on T-Cell Lines Is Associated with SDF-1α-Mediated Invasion and Phosphorylation of Signaling Molecules.

Characterization of Cancer Stem Cells in Human B-Cell Lymphoid Hematologic Malignancies.

A Novel Mechanism for Imatinib Mesylate (STI571) Resistance in CML Cells: Contribution of TC-PTP to Modulating Signals Down-Stream from the BCR-ABL Fusion Protein.

CD26/Dipeptidyl Peptidase IV (DPPIV) Regulates p38 Phosphorylation and Topoisomerase II Alpha Expression in the B-Lymphoma Line Jiyoye, Associated with Enhanced In Vitro and In Vivo Sensitivity to Doxorubicin.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only